A. Wright

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Wolfgang Hueber, Dhavalkumar D. Patel, Thaddeus P. Dryja et al. · Science Translational Medicine · 2010 · 858 citations

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

Dominique Baeten, Xenofon Baraliakos, Jürgen Braun et al. · The Lancet · 2013 · 585 citations

Inflammation, Rheumatology, Rheumatoid Disorder +12

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study

Eva Havrdová, Anna N. Belova, Alla Goloborodko et al. · Journal of Neurology · 2016 · 214 citations

Inflammation, Neuro-oncology, Brain Lesions +12

The human anti-IL-1β monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis

Rieke Alten, Hermann Gram, Leo A. B. Joosten et al. · Arthritis Research & Therapy · 2008 · 163 citations · Full text

Supplementary Materials for Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

Wolfgang Hueber, Dhavalkumar D. Patel, Thaddeus P. Dryja et al. · 2010 · 151 citations

Inflammation, Rheumatology, Rheumatoid Disorder +9